- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, December 20, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An InsideSources article referenced a study published in the August 2019 issue of The American Journal of Managed Care® (AJMC®). The study, “Influence of Out-of-Network Payment Standards on Insurer—Provider Bargaining: California’s Experience,” details the impact of California’s out-of-network payment standards on price and network breadth.
A piece by Science Blog highlighted a study published in the December 2019 issue of AJMC®, “Benzodiazepine and Unhealthy Alcohol Use Among Adult Outpatients.” The study found that among outpatients who were screened for alcohol use, those with unhealthy alcohol use, women, and those who were older, white, and of lower socioeconomic status were more likely to use benzodiazepines.
A news release on Global Health News Wire, “Out-of-network costs soar for non-emergency hospitalizations,” covered a study published in the December 2019 issue of AJMC® titled “Cost-Sharing Payments for Out-of-Network Care in Commercially Insured Adults,” which described how the out-of-pocket financial burden for insured working Americans is substantial and growing.
A study published in the December 2012 issue of AJMC®, “Personalized Preventive Care Leads to Significant Reductions in Hospital Utilization,” assessed the impact of the MDVIP personalized preventive care model on hospital utilization and found the MDVIP members’ rates were substantially lower than nonmembers’. The study was featured in an article by Iosco County News-Herald.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
January 13th 2025A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Read More
